JNJ RSI

What is JNJ?

Founded in 1886 by the Johnson brothers, Johnson & Johnson originally revolutionized the medical world with sterile surgical dressings. Since then, it has transformed into a diversified healthcare titan. After spinning off its consumer health business in 2023, JNJ now operates with a laser focus on two high-growth segments: Innovative Medicine and MedTech. This shift allows the company to focus resources on complex science and high-margin innovation rather than retail goods.

The Innovative Medicine arm is a clinical powerhouse, driven by blockbuster treatments in immunology, oncology, and neuroscience. Products like Stelara and Darzalex have become cornerstones of their revenue, while their emerging pipeline of CAR-T cell therapies represents the next frontier of cancer care. In the MedTech space, JNJ is a world leader in orthopedics, vision, and surgery. Recent acquisitions like Abiomed and the ongoing development of the Ottava robotic system show their deep commitment to heart recovery and digitally-enabled surgery.

Historically, JNJ has navigated massive shifts, from inventing the first-aid kit to becoming a global leader in biotechnology through aggressive acquisitions like Actelion. Financially, they are one of the most stable companies on the planet, holding a rare AAA credit rating and a sixty-year streak of annual dividend increases. While they face significant legal hurdles regarding legacy talc products, their operating margins and free cash flow remain incredibly healthy.

Looking toward 2026, JNJ is positioning itself for a new era of growth. Management is targeting nearly $60 billion in pharmaceutical sales by 2025, with 2026 serving as the pivotal year to offset losses from the Stelara patent cliff through a massive wave of new product launches. You should expect them to remain very aggressive in the M&A market, likely snapping up mid-sized biotech firms to bolster their late-stage pipeline. For a long-term play, JNJ offers a unique mix of defensive stability and exposure to the most advanced medical technology currently under development.

What is RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and magnitude of price changes. Developed by J. Welles Wilder, RSI ranges from 0 to 100 and helps traders identify overbought or oversold conditions in an asset.

For JNJ, monitoring the RSI provides valuable insights into potential trend reversals and entry/exit points. When the RSI drops below 30, Johnson & Johnson is typically considered oversold, suggesting the asset may be undervalued. Conversely, an RSI above 70 indicates overbought conditions.

Understanding JNJ RSI Signals

• Oversold (RSI below 30): When JNJ RSI falls below 30, it suggests the asset may have been sold off excessively and could be due for a bounce. This is often viewed as a potential buying opportunity, though it's important to consider other factors and not rely solely on RSI.
• Overbought (RSI above 70): An RSI above 70 indicates JNJ may be overbought, potentially signaling a pullback or consolidation phase. Traders often use this as a signal to take profits or wait for better entry points.
• Divergences: When JNJ price makes new highs or lows but RSI doesn't confirm these moves, it can signal weakening momentum and a possible trend reversal.

Daily vs Weekly RSI for JNJ

This page displays both daily and weekly RSI for JNJ. The daily RSI responds quickly to short-term price movements, making it useful for day traders and swing traders. The weekly RSI provides a broader perspective on momentum trends, helping longer-term investors identify major oversold or overbought conditions.

By analyzing both timeframes together, you can better understand Johnson & Johnson's momentum at multiple levels and make more informed trading decisions.

Historical RSI Oversold Analysis

Above, we track historical instances when JNJ RSI dropped below 30 (oversold territory). Reviewing these past oversold levels helps identify patterns and understand how Johnson & Johnson has historically responded to oversold conditions. Many traders use these historical reference points to gauge potential support levels and timing for entry positions.